Filing Details
- Accession Number:
- 0001491877-12-000022
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-04-09 13:00:00
- Reporting Period:
- 2012-04-05
- Filing Date:
- 2012-04-09
- Accepted Time:
- 2012-04-09 16:21:31
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
72444 | Nabi Biopharmaceuticals | NABI | Biological Products, (No Disgnostic Substances) (2836) | 591212264 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1428524 | D. Paul Kessler | C/O Nabi Biopharmaceuticals 12270 Wilkins Ave Rockville MD 20852 | Svp Clinical, Med. & Reg.; Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2012-04-05 | 5,167 | $1.90 | 105,128 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- This disposition was effected pursuant to a 10b-5 trading plan and was made to fund the Reporting Person's tax obligation arising from the vesting of restricted stock.